E-therapeutics Share Discussion Threads

[herb clark] 27/6/2019 09:01

Data it and Woody please can you take your puerile messages elsewhere

[woolybadger62] 27/6/2019 08:57

Broker target of 24pHold on to your hats

[datait] 27/6/2019 08:54

PMSL Wooly your locked in you fanny, nobody wants the shares and certainly not at that spread. win win for mm's either way hahahaha
dahhhh dahhhh dahhhhhh

[woolybadger62] 27/6/2019 08:51

On HL YOU CAN sell a max of 32000 shares for live price otherwise is Nt

[soupdragon55] 27/6/2019 08:50

Herb, the only person who can answer as to why you can't sell is your broker. Ring them and ask why.

Nobody here can tell you why your broker won't deal.

[pre] 27/6/2019 08:46

should get rns today confirming he's out.

[woolybadger62] 27/6/2019 08:39

That's a live quote if you put in a limit order prob will get filled

[herb clark] 27/6/2019 08:37

Actually Woody I am interested to know why it is permanently NT to sell

[woolybadger62] 27/6/2019 08:27

I've noticed that herb Clark seems to always ask the same questions around the aim sharesWhy is thisWhy is thatCould it be thisCould it be that

[h2owater] 27/6/2019 08:24

26p according to RNS



Tuesday 05 March, 2019

Edison Investment Research Lim

05-March-2019 / 15:51 GMT/BST


London, UK, 5 March 2019

Edison issues update on e-Therapeutics (ETX)

e-Therapeutics' (ETX) FY19 results demonstrated continued financial prudence and its focus on partnering, out-licensing and non-dilutive financing. The FY19 operating loss was £5.1m, which is the same as our estimate. The cash outflow was £3.7m, resulting in a cash balance of £5.9m at the end of FY19. Both R&D and administrative expenses had been reduced from FY18 and the recently announced Novo collaboration generated £0.04m in FY19.

We have updated our valuation to £69.4m or 26p/share, from £63.5m (24p/share), due to the impact of a stronger dollar on the dollar-based comparative transactions. All underlying assumptions remain unchanged. ETX expects more collaborations, and more visible transactions than the Novo collaboration and we would expect these to be incorporated into ETX's valuation when they occur.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website
www.edisoninvestmentresearch.com

[herb clark] 27/6/2019 08:23

Not consistently though

[tidy 2] 27/6/2019 08:22

Herb you had the same problem on IQA, Skin and NFX etc etc. How peculiar;)

[woolybadger62] 27/6/2019 08:18

Might be Woodford who has first dips on sells